JPMorgan Chase & Co. Has $462,000 Position in LifeMD, Inc. (NASDAQ:LFMD)

JPMorgan Chase & Co. boosted its holdings in shares of LifeMD, Inc. (NASDAQ:LFMD) by 496.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 88,173 shares of the company’s stock after buying an additional 73,389 shares during the period. JPMorgan Chase & Co. owned approximately 0.20% of LifeMD worth $462,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. nVerses Capital LLC purchased a new position in shares of LifeMD during the third quarter valued at approximately $46,000. Intech Investment Management LLC bought a new stake in shares of LifeMD in the 3rd quarter worth $54,000. CWM LLC purchased a new stake in shares of LifeMD in the third quarter valued at about $59,000. SG Americas Securities LLC bought a new position in shares of LifeMD during the third quarter valued at about $70,000. Finally, The Manufacturers Life Insurance Company purchased a new position in LifeMD during the second quarter worth about $93,000. 35.52% of the stock is owned by institutional investors.

LifeMD Stock Performance

Shares of LFMD opened at $5.50 on Wednesday. LifeMD, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $12.88. The business has a 50-day moving average of $5.44 and a 200 day moving average of $5.39. The firm has a market cap of $238.21 million, a P/E ratio of -8.59 and a beta of 1.49.

LifeMD (NASDAQ:LFMD) last posted its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.05). The firm had revenue of $53.39 million for the quarter, compared to analysts’ expectations of $53.53 million. During the same period last year, the firm earned ($0.20) EPS. As a group, research analysts predict that LifeMD, Inc. will post -0.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on LFMD. KeyCorp decreased their price objective on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of LifeMD in a report on Monday, November 11th. Mizuho started coverage on LifeMD in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price objective for the company. Finally, Lake Street Capital initiated coverage on LifeMD in a research report on Tuesday, December 10th. They set a “buy” rating and a $12.00 target price for the company. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.14.

Insiders Place Their Bets

In related news, CEO Justin Schreiber sold 25,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $5.19, for a total transaction of $129,750.00. Following the sale, the chief executive officer now directly owns 2,703,715 shares in the company, valued at approximately $14,032,280.85. The trade was a 0.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 15.97% of the company’s stock.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.